RYTHMOIRESEARCH
SMS Research Updates ↗

MDT / Healthcare

Medtronic plc

Electromedical & Electrotherapeutic Apparatus

Company overview

Medtronic plc is an SEC-reporting issuer listed on NYSE under MDT. Its SEC industry description is Electromedical & Electrotherapeutic Apparatus. This profile organizes annual financial disclosures for research; sector labels are editorial groupings, not GICS classifications.

Drug developers, device manufacturers and care providers depend on distinct clinical, reimbursement and operating economics.

Business segments

Segment-level revenue is not included in this standardized dataset. Consult the business and segment notes in the linked annual filing for the issuer’s actual reporting segments.

Selected fundamentals

Annual reporting currency: USD. Financial amounts are in millions, except per-share figures and ratios.

Latest period 2026-04-24 · prior period 2025-04-25
Metric2026-04-242025-04-25Source filed
RevenueUSD 36,364mUSD 33,537m2026-06-18
Operating incomeUSD 6,467mUSD 5,955m2026-06-18
Net incomeUSD 4,801mUSD 4,662m2026-06-18
Diluted EPSUSD 3.73USD 3.612026-06-18
Operating cash flowUSD 7,330mUSD 7,044m2026-06-18
Capital expenditureUSD 1,904mUSD 1,859m2026-06-18
Free cash flowUSD 5,426mUSD 5,185m2026-06-18
Gross marginNot availableNot available2026-06-18
Operating margin17.78%17.76%2026-06-18

FCF = operating cash flow − purchases of property, plant and equipment. Missing tags remain unavailable. Standardized cash-flow comparisons are particularly limited for financial businesses.

Inspect original metric provenance
{
  "revenue": {
    "start": "2025-04-26",
    "end": "2026-04-24",
    "val": 36364000000,
    "accn": "0001628280-26-044354",
    "fy": 2026,
    "fp": "FY",
    "form": "10-K",
    "filed": "2026-06-18",
    "frame": "CY2025",
    "tag": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
    "unit": "USD"
  },
  "netIncome": {
    "start": "2025-04-26",
    "end": "2026-04-24",
    "val": 4801000000,
    "accn": "0001628280-26-044354",
    "fy": 2026,
    "fp": "FY",
    "form": "10-K",
    "filed": "2026-06-18",
    "tag": "us-gaap:NetIncomeLoss",
    "unit": "USD"
  },
  "operatingIncome": {
    "start": "2025-04-26",
    "end": "2026-04-24",
    "val": 6467000000,
    "accn": "0001628280-26-044354",
    "fy": 2026,
    "fp": "FY",
    "form": "10-K",
    "filed": "2026-06-18",
    "frame": "CY2025",
    "tag": "us-gaap:OperatingIncomeLoss",
    "unit": "USD"
  },
  "eps": {
    "start": "2025-04-26",
    "end": "2026-04-24",
    "val": 3.73,
    "accn": "0001628280-26-044354",
    "fy": 2026,
    "fp": "FY",
    "form": "10-K",
    "filed": "2026-06-18",
    "frame": "CY2025",
    "tag": "us-gaap:EarningsPerShareDiluted",
    "unit": "USD/shares"
  },
  "operatingCashFlow": {
    "start": "2025-04-26",
    "end": "2026-04-24",
    "val": 7330000000,
    "accn": "0001628280-26-044354",
    "fy": 2026,
    "fp": "FY",
    "form": "10-K",
    "filed": "2026-06-18",
    "frame": "CY2025",
    "tag": "us-gaap:NetCashProvidedByUsedInOperatingActivities",
    "unit": "USD"
  },
  "capex": {
    "start": "2025-04-26",
    "end": "2026-04-24",
    "val": 1904000000,
    "accn": "0001628280-26-044354",
    "fy": 2026,
    "fp": "FY",
    "form": "10-K",
    "filed": "2026-06-18",
    "frame": "CY2025",
    "tag": "us-gaap:PaymentsToAcquirePropertyPlantAndEquipment",
    "unit": "USD"
  },
  "totalAssets": {
    "end": "2026-04-24",
    "val": 93028000000,
    "accn": "0001628280-26-044354",
    "fy": 2026,
    "fp": "FY",
    "form": "10-K",
    "filed": "2026-06-18",
    "tag": "us-gaap:Assets",
    "unit": "USD"
  },
  "totalLiabilities": {
    "end": "2026-04-24",
    "val": 42956000000,
    "accn": "0001628280-26-044354",
    "fy": 2026,
    "fp": "FY",
    "form": "10-K",
    "filed": "2026-06-18",
    "tag": "us-gaap:Liabilities",
    "unit": "USD"
  },
  "shareholdersEquity": {
    "end": "2026-04-24",
    "val": 49463000000,
    "accn": "0001628280-26-044354",
    "fy": 2026,
    "fp": "FY",
    "form": "10-K",
    "filed": "2026-06-18",
    "tag": "us-gaap:StockholdersEquity",
    "unit": "USD"
  },
  "currentAssets": {
    "end": "2026-04-24",
    "val": 24787000000,
    "accn": "0001628280-26-044354",
    "fy": 2026,
    "fp": "FY",
    "form": "10-K",
    "filed": "2026-06-18",
    "tag": "us-gaap:AssetsCurrent",
    "unit": "USD"
  },
  "currentLiabilities": {
    "end": "2026-04-24",
    "val": 11658000000,
    "accn": "0001628280-26-044354",
    "fy": 2026,
    "fp": "FY",
    "form": "10-K",
    "filed": "2026-06-18",
    "tag": "us-gaap:LiabilitiesCurrent",
    "unit": "USD"
  }
}

Annual earnings trend

Reported fiscal periods, not a live price chart.

Interactive chart loads in the browser. The full annual values are available below.

View all annual figures in a table
Period endRevenueNet incomeEPS
2026-04-24USD 36,364mUSD 4,801mUSD 3.73
2025-04-25USD 33,537mUSD 4,662mUSD 3.61
2024-04-26USD 32,364mUSD 3,676mUSD 2.76
2023-04-28USD 31,227mUSD 3,758mUSD 2.82

Valuation context

This release does not quote price-based multiples because it does not include synchronized market prices. A financial denominator must be paired with a clearly dated market value.

MeasureInterpretation
P/EPrice divided by EPS; identify annual, trailing or forward basis.
P/S & P/BMarket capitalization divided by sales or book equity.
EV / EBITDAEnterprise value and EBITDA need consistent definitions.
FCF yieldFree cash flow divided by dated market capitalization.

A sector median is descriptive, not a fair-value estimate. Explore sector context ↗

Selected filing notes

No filing note selected for this company in this release. Annual source filings remain available below.

Related research

Risks & what to monitor

Patent expiry, trial outcomes, reimbursement changes, litigation and acquisition integration.

Product concentration, research investment, utilization, reimbursement and cash generation.

Sources & dates